CTP 354

Drug Profile

CTP 354

Alternative Names: C-21191; CTP-354; D-L838417

Latest Information Update: 02 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Concert Pharmaceuticals
  • Class Analgesics; Antispastics; Fluorobenzenes; Organic deuterium compounds; Pyridazines; Small molecules; Triazoles
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Muscle spasticity; Neuropathic pain

Most Recent Events

  • 01 Jan 2015 Suspended - Phase-I for Muscle spasticity and Neuropathic pain (In volunteers) in USA (PO)
  • 13 Oct 2014 Adverse events & pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 139th Annual Meeting of the American Neurological Association (ANA-2014)
  • 01 Oct 2014 Concert Pharmaceuticals completes a phase I trial in Healthy volunteers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top